Articles Tagged With: Pharmacology
-
Psychiatric Medications and Long QT Syndrome: A Safe Combination?
A retrospective study of patients with electrocardiogram long QT interval syndrome and psychiatric disease suggests that with proper pharmacologic treatment and counseling, the patients can be treated safely with psychiatric drugs known to increase the QT interval.
-
Brensocatib Tablets (Brinsupri)
The U.S. Food and Drug Administration has approved brensocatib, the first dipeptidyl peptidase-1 inhibitor and the first drug approved for non-cystic fibrosis bronchiectasis.
-
Sunvozertinib (Zegfrovy) Tablets
The U.S. Food and Drug Administration (FDA) has granted an accelerated approval to sunvozertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) for the treatment of non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (EGFR exon20ins). The FDA also approved a companion diagnostic device, Oncomine Dx Express Test to help detect exon20ins mutations.
-
Fidaxomicin Is More Clinically Effective than Vancomycin for C. difficile Infection
There is a lack of real-world data on using fidaxomicin for Clostridioides difficile infection (CDI). A retrospective, single-center study found that treatment of CDI with fidaxomicin leads to reduced clinical failure compared to oral vancomycin.
-
Lenacapavir Injection and Tablets (Yeztugo)
The U.S. Food and Drug Administration has approved lenacapavir, a potent, first-in-class, capsid inhibitor, for reducing the risk of sexually acquired human immunodeficiency virus type 1.
-
Avutometinib Capsules and Defactinib Tablets (Avmapki Fakzynja CO-PACK)
The U.S. Food and Drug Administration has granted accelerated approval for a combination of two kinase inhibitors, avutometinib and defactinib, for the treatment of KRAS-mutated recurrent low-grade serous ovarian cancer who have received prior systemic therapy, including a platinum-based regimen.
-
Telisotuzumab Vedotin-tlly (Emrelis)
The U.S. Food and Drug Administration has granted accelerated approval of telisotuzumab vedotin-tilly, a first-in-class c-mesenchymal-epithelial transition factor-directed antibody and a microtubule inhibitor conjugate for the treatment of locally advanced or metastatic, non-squamous non-small cell lung cancer.
-
New Injectable Cholesterol-Lowering Drug Trial
A comparison of inclisiran therapy to placebo and ezetimibe therapy over six months in primary prevention patients at low risk of atherosclerotic cardiovascular disease and not taking lipid-lowering therapy has shown that inclisiran subcutaneously every six months reduces low-density lipoprotein cholesterol more than ezetimibe and is comparable to the reported results of high-dose statins taken daily.
-
Nipocalimab-aahu Injection (Imaavy)
The U.S. Food and Drug Administration has approved a neonatal Fc-receptor (FcRn) blocker for the treatment of generalized myasthenia gravis. Nipocalimab-aahu is a recombinant human immunoglobulin G1 lambda monoclonal antibody directed at FcRn with high affinity and selectivity.
-
Gepotidacin Tablets (Blujepa)
The U.S. Food and Drug Administration has approved gepotidacin, a first-in-class antibacterial medication for the treatment of uncomplicated urinary tract infections.